Market News & Trends
BioStem Technologies Announces Letter of Intent With CCM Pharma Solutions
BioStem Technologies, Inc. recently announced it has signed a Letter of Intent with CCM Pharma Solutions. CCM has identified several drugs in the cardiovascular, metabolic…
MedPharm Receives Growth Equity Investment From Ampersand Capital Partners
MedPharm Ltd., a leading provider of contract topical and transdermal product design and formulation development services, recently announced a multi-million dollar investment by Ampersand Capital…
Organovo Division Samsara Sciences Announces Multi-Year Supply Agreement With Lonza Bioscience Solutions
Organovo Holdings, Inc. recently announced its wholly owned subsidiary, Samsara Sciences, Inc., a provider of highly specialized human liver cells, entered a non-exclusive global supply…
Nuvaira Announces First Patient Treated in RELIEF-1 Study Evaluating New Approach for Asthma Treatment
Nuvaira recently announced treatment of the first patient in the RELIEF-1 Clinical Study in Europe. The RELIEF-1 trial (NCT02872298) is a prospective, multi-center, single-arm (non-randomized)…
SetPoint Medical Announces Trial to Evaluate First Bioelectronic Device
SetPoint Medical recently announced it has launched a pilot trial for patients with drug refractory rheumatoid arthritis (RA) in the US. The multi-center study, A…
RedShiftBio Announces Collaboration Trial Completion
RedShift BioAnalytics, Inc. (RedShiftBio), a provider of analytical instrumentation for the characterization of protein therapeutics, recently announced the completion of Phase II of the company’s…
Inovio Closes License & Collaboration Agreement With ApolloBio
Inovio Pharmaceuticals, Inc. recently announced it has closed an agreement providing ApolloBio Corp. with the exclusive right to develop, manufacture, and commercialize VGX-3100, Inovio’s DNA…
Elligo Health Research Raises $16 Million to Improve Access to Clinical Trials
Elligo Health Research, which improves clinical trial access by engaging the 97% of physicians currently not offering clinical research to their patients, recently announced $16…
Cesca Therapeutics Expands CAR-TXpress Intellectual Property Portfolio
Cesca Therapeutics Inc. recently announced its device subsidiary, ThermoGenesis Corp., has filed a patent with the US PTO for a method of further simplifying the…
Innovest Global Signs Letter of Intent to Acquire 20% of StemVax Therapeutics
Innovest Global Inc. recently announced it has signed a Letter of Intent to acquire a 20% stake in StemVax LLC. StemVax is a Translational Biotechnology…
US PTO Awards BioPharmX Patent Protection for Novel Tetracycline-Class Topical Drug Compositions
BioPharmX Corporation recently announced the US PTO has granted the first in what the company expects will be a new family of patents protecting its…
BioDuro Collaboration With Pfizer Leads to Creation of a Shelf-Stable Fluorosulfation Reagent
BioDuro LLC recently announced the creation of AISF ([4-(Acetylamino)phenyl]-ImidodiSulfuryl diFluoride), a convenient, shelf-stable, crystalline reagent for the synthesis of fluorosulfates and sulfamoyl fluorides. AISF was…
ERT Launches Phase I Site Certification Program to Improve Efficiencies in Clinical Development
ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, recently announced it has launched a certification program for Phase…
Helsinn Group Announces First Patient Enrolled in Phase 3b Study of NEPA IV Versus NEPA Oral
Helsinn recently announced that the first patient has been enrolled in a Phase 3b study to assess the safety and tolerability of IV NEPA fixed…
Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial
Sienna Biopharmaceuticals, Inc. recently announced that the first patient has been dosed in the company’s Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125…
DuPont’s Microbiome Venture Announces Second Strategic Partnership
Three months after its formation, the DuPont Nutrition & Health Microbiome Venture recently announced its second strategic research and development partnership. The newly forged relationship…
SanBio Reaches Agreement on Manufacture of Regenerative Medicine Product With Hitachi Chemical
SanBio Group and Hitachi Chemical Co., Ltd. jointly announced that, through an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LCC, they will manufacture SB623, a…
Newly Issued US Patent Covers Spotlight Innovation's Spinal Muscular Atrophy Drug Candidates
Spotlight Innovation Inc. recently announced that US Patent No. 9,895,358, titled Combination Therapies for Treatment of Spinal Muscular Atrophy, has been issued to Indiana University…
Dalton Announces a Drug Development & GMP Manufacturing Services Agreement With Oryn Therapeutics
Dalton Pharma Services has recently announced the signing of a drug development and manufacturing services agreement with Oryn Therapeutics, an American biotechnology firm committed to…
Gerresheimer Unveils Innovative Vials Made From Glass & Plastic
Gerresheimer’s booth at the PDA Annual Meeting – held at the Loews Sapphire Falls Resort in Orlando from March 19 to 21 – was to…
